Paris, France, December 14, 2022

Servier and Gustave Roussy sign a framework agreement for a strategic collaboration in oncology and immuno-oncology

A long-term strategic collaboration on an R&D program in adult and pediatric oncology

Servier, a global pharmaceutical group, and Gustave Roussy, a leading cancer treatment center in Europe, announce the signing of a framework agreement relating to collaborative projects in oncology and immuno-oncology.

This renewable four-year agreement formalizes a strategy of a long-term collaboration between Servier and Gustave Roussy, who share the common goal of cancer research and treatment. It is the reference framework for the co-development of fundamental and translational research for the benefit of cancer patients. The agreement also includes early phase clinical trials with innovative molecules from Servier's oncology pipeline to be conducted by Gustave Roussy.

At this time, five research and development projects in adult and pediatric oncology will be launched. They concern indications of interest developed by Servier and, in particular, certain indications that Gustave Roussy consider to be still associated with unmet needs. These projects concern both the development of new preclinical models and the identification of predictive biomarkers to optimize therapeutic management.  

Claude Bertrand, Executive Vice-President R&D of Servier, states: “We are delighted with the signing of this framework agreement, which is a continuation of the constructive collaboration initiated several years ago with Gustave Roussy, recognized for its substantial expertise and advanced research capacities in oncology. This agreement illustrates Servier's commitment to oncology and its strong collaborative innovation dynamics to accelerate the discovery of innovative therapeutic solutions for patients. The opening of the Servier R&D institute within the Paris-Saclay global innovation hub in the first half of 2023 will provide a new dimension to this strategic partnership. “

Prof. Fabrice Barlesi, CEO of Gustave Roussy, adds: "The framework agreement we are signing today with Servier is strategic for patients living with cancer. It is the culmination of a long-standing collaboration that will eventually be reflected in the Paris-Saclay Cancer Cluster. The first research projects in hematology, immuno-oncology and pediatrics illustrate the scope and momentum that this agreement will further boost our collaboration."

Prof. Angelo Paci, Program Leader Oncology and Immuno-onco at Servier, emphasizes: “This collaboration allows combining the expertise of Servier and Gustave Roussy, with the common objective of initiating ambitious R&D projects for purposes of developing therapeutic innovations targeting resistant cancers, such as certain acute myeloid leukemias in adults, and treatments targeting cancers with high unmet needs, such as certain brain tumors in children.”